We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Biovica International AB (BIOVIC B) NPV B

Sell:2.70 SEK Buy:2.75 SEK Change: 0.24 SEK (9.36%)
Market closed |  Prices as at close on 6 December 2024 | Switch to live prices |
Sell:2.70 SEK
Buy:2.75 SEK
Change: 0.24 SEK (9.36%)
Market closed |  Prices as at close on 6 December 2024 | Switch to live prices |
Sell:2.70 SEK
Buy:2.75 SEK
Change: 0.24 SEK (9.36%)
Market closed |  Prices as at close on 6 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Contact details

Address:
Dag Hammarskjolds vag 54B
Uppsala Science Park
UPPSALA
752 37
Sweden
Telephone:
+46 (18) 4444830
Website:
https://biovica.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BIOVIC B
ISIN:
SE0008613731
Market cap:
211.03 million SEK
Shares in issue:
84.06 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Anders Rylander
    Chief Executive Officer, Director
  • Anders Moren
    Chief Financial Officer
  • Henrik Winther
    Senior Vice President - Business Development
  • Helle Fisker
    Vice President - Commercial and Marketing
  • Hanna Ritzen
    Vice President - Research & Development
  • Hector Tamburini
    Head of US Laboratory Operations, Regulatory & Quality

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.